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Strengths and limitations of this study
 ► The qualitative methodology employed in this study 
facilitated an in- depth exploration of interviewees’ 
perspectives and allowed them to express their 
views in their own words; however, the sample 
size was small and encompassed only four London 
hospitals which brought limitations for wider gen-
eralisability and did not allow between group 
comparisons.
 ► Some of the interviewees were ‘consenters’ from 
the 100 000 Genomes Project so although they had 
real experience of supporting patients during the 
informed consent process, most would not be de-
livering genome sequencing clinically in the future.
 ► Interviewees also included a range of genetic and 
non- genetic healthcare professionals from multiple 
hospital sites who will be responsible for deliver-
ing genome sequencing in the new UK Genomic 
Medicine Service.
 ► Interviewees’ views were informed by their expe-
rience of actually offering genome sequencing to 
National Health Service patients, rather than views 
being entirely based on hypothetical scenarios; 
however, at the time of the interviews very few re-
sults had been returned from the 100 000 Genomes 
Project.
 ► Our findings shed important light on where the ev-
idence gaps about clinical genome sequencing are 
from healthcare professionals’ perspectives; this 
information may also be of use to practitioners and 
policy- makers concerned with delivering genome 
sequencing clinically going forwards.
ABSTRACT
Objectives Genome sequencing is poised to be 
incorporated into clinical care for diagnoses of rare 
diseases and some cancers in many parts of the world. 
Healthcare professionals are key stakeholders in the 
clinical delivery of genome sequencing- based services. 
Our aim was to explore views of healthcare professionals 
with experience of offering genome sequencing via the 
100 000 Genomes Project.
Design Interview study using thematic analysis.
Setting Four National Health Service hospitals in London.
Participants Twenty- three healthcare professionals 
(five genetic clinicians and eight non- genetic clinicians 
(all consultants), and 10 ‘consenters’ from a range of 
backgrounds) involved in identifying or consenting patients 
for the 100 000 Genomes Project.
Results Most participants expressed positive attitudes 
towards genome sequencing in terms of improved ability 
to diagnose rare diseases, but many also expressed 
concerns, with some believing its superiority over exome 
sequencing had not yet been demonstrated, or worrying 
that non- genetic clinicians are inadequately prepared 
to discuss genome sequencing results with patients. 
Several emphasised additional evidence about utility of 
genome sequencing in terms of both main and secondary 
findings is needed. Most felt non- genetic clinicians could 
support patients during consent, as long as they have 
appropriate training and support from genetic teams. 
Many stated genetics experts will play a vital role in 
training and supporting non- genetic clinicians in variant 
interpretation and results delivery, particularly for more 
complex cases.
Conclusions Healthcare professionals responsible 
for delivering clinical genome sequencing have largely 
positive views about the potential for genome sequencing 
to improve diagnostic yield, but also significant concerns 
about practical aspects of offering these tests. Non- 
genetic clinicians delivering genome sequencing require 
guidance and support. Additional empirical evidence 
is needed to inform policy and practice, including how 
genome compares to exome sequencing; utility of 
secondary findings; training, in particular of non- genetic 
health professionals; and mechanisms whereby genetics 
teams can offer appropriate support to their non- genetics 
colleagues.
BACkgROunD
Genome sequencing is increasingly being 
incorporated into clinical care for the 
purposes of diagnosing rare disease and 
some cancers. Genome sequencing allows 
us to determine most of a person’s complete 
set of DNA by interrogating both the coding 
and non- coding regions of the genome. This 
contrasts with exome sequencing which only 
looks at the coding regions of the genome or 
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more targeted approaches that use gene panels to focus 
on specific sub- sets of candidate genes. Exome sequencing 
and panel testing have been widely used in both research 
and clinical settings, but as costs come down greater use of 
genome sequencing is occurring. Genome sequencing is 
more comprehensive than exome sequencing, with wider 
genome coverage and growing evidence of improved 
diagnostic yield in some contexts.1 However, the poten-
tial for genomic sequencing to identify a wider range of 
variants as well as secondary findings that are unrelated to 
the indication for testing is a key consideration for imple-
mentation as this adds to the complexity of consent and 
return of results processes.
In the National Health Service (NHS) in England a 
new Genomic Medicine Service was launched in October 
2018 that will include offering genome sequencing for 
patients with undiagnosed rare genetic diseases or a 
current diagnosis of cancer. A National Test Directory has 
been developed that describes the full range of tests avail-
able. The eligibility, testing and consent materials will be 
standardised across the Genomic Medicine Service.2 The 
springboard for this new service had been the 100 000 
Genomes Project which, under research consent and 
governance, recruited patients with rare diseases (chil-
dren and adults) and their relatives, and patients with 
cancer, for genome sequencing between 2015 and 2018. 
Recruitment was conducted through 13 NHS Genomic 
Medicine Centres (GMCs) located across the UK. In 
addition to receiving the main findings relevant to the 
indication for testing, participants could also opt in to 
secondary findings being looked for by the project scien-
tists. The list of looked for secondary findings includes 
variants in genes that increase predisposition to breast 
and ovarian cancer (including BRCA1 and BRCA2), 
Lynch syndrome (colorectal cancer and other cancers) 
and familial hypercholesterolaemia. Participants could 
also opt in to secondary analysis of their genomic data to 
determine carrier status for cystic fibrosis. The return of 
main and secondary findings from the 100 000 Genomes 
Project is ongoing and participants are being given their 
results through NHS clinical pathways.
In England as elsewhere, there are efforts to main-
stream genomic testing such that, when indicated, both 
genetic and non- genetic clinicians will be able to order 
genome sequencing for their patients, as they would 
other clinical tests. The main stated benefits of genome 
sequencing for rare disease diagnoses include increased 
discovery rate of causative gene variants, the potential to 
dramatically shorten the ‘diagnostic odyssey’, preventing 
multiple, often invasive and expensive, investigations and 
allowing targeted therapies.3 However, moving genome 
sequencing from research to clinical practice raises 
many challenges. These include how to ensure there is 
the relevant expertise and infrastructure to deliver clin-
ical genome sequencing nationally; whether non- genetic 
clinicians need support to offer genome sequencing and 
return results to patients as genomics is mainstreamed, 
and if so, what kind of support; and what results should 
be returned and to whom? While many of these ques-
tions arise in the context of other types of genetic tests, 
particularly exome sequencing, the potential challenges 
are even greater in the context of genome sequencing 
because of the sheer volume of data generated for any 
given individual or family.
Healthcare professionals are key stakeholders in 
answering these questions given they are central to 
offering genome sequencing to patients, facilitating 
informed consent, supporting patients’ decision- making 
and returning results to patients. Previous studies have 
explored healthcare professionals’ experiences of 
obtaining informed consent for genomic sequencing4–6 
and returning genomic results,7 8 and views regarding 
secondary findings from genomic sequencing.9 10 Most 
of these studies were conducted in the USA,4–9 one in 
Canada10 and the only UK study to date drew on expe-
riences of a single multidisciplinary team (MDT) and 
focused exclusively on secondary findings.11
The 100 000 Genomes Project affords a unique oppor-
tunity to gather stakeholder views on the implemen-
tation of genome sequencing in the setting of a large 
scale, nationally implemented initiative where healthcare 
is state funded and the intention is to return clinically 
relevant diagnoses. Here we aim to explore views of a 
range of healthcare professionals involved in the 100 000 
Genomes Project regarding moving genome sequencing 
for rare disease diagnoses into clinical practice within the 
new Genomic Medicine Service, with a view to providing 
insights that may be relevant to policy and practice.
Methods
Study design
A qualitative approach using one- to- one interviews for 
data collection was used to facilitate in- depth explora-
tion of healthcare professionals’ viewpoints on moving 
genome sequencing into NHS clinical practice.
Patient and public involvement
The advisory team for this study had one lay- person and 
three patient support group representatives; including 
co- author BS, who has also contributed to the revision of 
the manuscript. Over the course of the study the advisory 
team has provided ongoing review and feedback on study 
conduct, research materials, interpretation of data and 
reporting of findings.
Sampling and recruitment
Participants were recruited from four London hospitals 
that were part of two Genomic Medicine Centres (GMCs) 
recruiting affected individuals and their relatives into the 
100 000 Genomes Project. Three groups of health profes-
sionals were recruited to the study: (1) genetic and (2) 
non- genetic clinicians involved in identifying patients 
eligible to take part in the 100 000 Genomes Project; and 
(3) ‘consenters’, that is, members of the 100 000 Genomes 
Project consenting teams whose role included consenting 
patients for genome sequencing. Potential participants in 
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this study were identified by our research team and invited 
to participate via an email which included participant 
information explaining the aims of the study (see online 
supplementary material). They were asked to contact the 
researchers (CL, MH, SS) if interested in participating. 
Written consent was obtained prior to the interviews to 
ensure informed and voluntary participation.
Participants were purposefully sampled across four 
London hospitals to ensure inclusion of participants from 
different geographical locations, various approaches 
to recruitment and clinicians from a range of clin-
ical backgrounds. Consenters in the 100 000 Genomes 
Project have a range of backgrounds, including genetic 
counselling, research and other post graduate training. 
All consenters are trained, including taking the online 
course, ‘Preparing for the consent conversation’ (https://
www. genomicseducation. hee. nhs. uk/ courses/ courses/ 
consent- ethics/). Interviews and analysis were under-
taken concurrently, and recruitment ceased when no new 
themes were emerging during the interviews.
Interviews
An interview guide was developed for this study by the 
investigators to explore participants’ experiences and 
views on (a) recruitment into and (b) return of results 
in the 100 000 Genomes Project, as well as their views 
on moving genome sequencing into clinical practice, 
and their professional background and training for the 
100 000 Genomes Project. To develop the interview guide, 
a first draft of a set of questions reflecting the aims of the 
project was drafted by one of the investigators (MH) with 
experience in qualitative research methods; this was iter-
atively refined via discussion with two other investigators 
(CL, SS) on the team also with experience in qualitative 
methods; minor revisions were then made to the inter-
view guide in response to questions that emerged during 
the first two interviews. There were two versions of the 
interview guide: one for clinicians and one for consenters 
(see online supplementary material). The consenter 
version included additional sections about views on more 
specific aspects of informed consent and patients’ experi-
ences. The interviews were conducted face- to- face or via 
telephone by CL, MH or SS.
Data analysis
Interviews were digitally recorded, transcribed verbatim 
and anonymised. Pseudonyms were then assigned to 
each participant. Data were analysed using the principles 
of thematic analysis.12 NVivo V.10 (QSR International, 
Australia) software was used to facilitate coding and data 
analysis.
The focus of the analyses was text segments relevant 
to moving genome sequencing for rare disease diagnosis 
into clinical practice, reflecting the aims of this study. The 
research team comprised three postdoctoral researchers 
(SCS, CL, MH) with expertise in conducting qualitative 
analyses, two genetic healthcare providers (CP, LSC) 
with experience supervising qualitative analyses and one 
patient advocate (BS). The transcripts were coded by SCS 
and MH. The two investigators independently coded the 
same transcript and developed a draft codebook, and 
the two versions of the codebooks were compared and 
combined into a single codebook. The two investigators 
then independently coded a second transcript: a Kappa 
was calculated and indicated good inter- rater reliability. 
From this point the two investigators independently 
coded the remaining transcripts into eight broad over-
arching categories. The overarching category specifically 
focused on moving genome sequencing into routine 
clinical practice was then coded line by line into mean-
ingful units of text. To ensure rigour and increase authen-
ticity, multiple investigators (SCS, CL, MH) with varying 
levels of familiarity with genome sequencing checked the 
emerging themes at multiple time points and together 
grouped the themes to form broader themes that were 
reviewed and redefined as the analysis progressed.
ReSulTS
Participants
The 23 participants were 5 genetic clinicians (all consul-
tants in clinical genetics), 8 non- genetic clinicians (all 
consultants, from a range of specialities including audi-
ology, paediatric nephrology, neurology and paediat-
rics) and 10 consenters (with a range of backgrounds, 
including nursing, project management, postdoctoral 
research and medical doctor trainees) from four hospital 
sites. See table 1 for additional participant characteristics. 
There were seven telephone and 16 face- to- face inter-
views. The interviews ranged in length from 19 to 75 min 
(median=34 min).
Overarching themes
Participants’ views on moving genome sequencing for 
rare disease diagnosis into clinical practice fell into 
three broad overarching themes; 1. Attitudes towards 
moving genome sequencing into clinical practice, 2. Atti-
tudes towards offering secondary findings from genome 
sequencing and 3. Views on how genome sequencing 
should be delivered in clinical practice.
Attitudes towards moving genome sequencing into clinical 
practice
Perceived benefits
Participants talked about three main ways in which clin-
ical genome sequencing will benefit patients. First, some 
participants felt that clinical genome sequencing will lead 
to improved diagnoses for patients with rare diseases 
by making the path to diagnosis more efficient, making 
it more likely patients will get a diagnosis with fewer 
tests needed. Second, some participants felt that clin-
ical genome sequencing will add to the knowledge base 
about rare diseases. Third, several participants talked 
about how research will lead to improved treatments for 
future patients, either by improving disease progression 
stratification or by personalising treatments based on 
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Table 1 Participant characteristics
Characteristic N (%)
Gender
  Female 19 (82.6)
  Male 4 (17.4)
Age
  20–30 years 7 (30.4)
  31–40 years 1 (4.3)
  41–50 years 8 (34.8)
  51–60 years 7 (30.4)
Role
Genetic clinician 5 (21.7)
Non- genetic clinician 8 (34.8)
  Audiovestibular medicine 2
  Neurology 2
  Neuromuscular 2
  Nephrology 2
Consenter 10 (43.5)
  Nursing 3
  Project management 1
  Laboratory research scientists 2
  Medical doctor trainees 1
  Other 3
Completed formal online training for 100 000 
Genomes Project
  Yes 13 (56.5)
  No 10 (43.5)
medication responsiveness (pharmacogenomics). See 
table 2 for illustrative quotes.
Concerns
Although many participants expressed positive attitudes 
towards genome sequencing, some also raised concerns. 
First, a few participants expressed concern that genome 
sequencing has not been demonstrated to be superior 
to exome sequencing for diagnosing rare diseases, and 
believed genome sequencing should not be introduced 
clinically until there is scientific evidence about its value. 
Second, many participants had concerns about informed 
consent, particularly around the time needed for this. 
Participants emphasised that the consent form for the 
100 000 Genomes Project was very long, and moreover that 
consent discussions had been undertaken by a dedicated 
consent team who would no longer be available after the 
transition to clinical practice. Some were concerned that 
some non- genetic clinicians do not understand the limita-
tions of genome sequencing sufficiently, and that they are 
therefore under- prepared to offer genome sequencing to 
their patients, for example:
"…having overheard conversations from colleagues, 
I don’t think they fully understand the limitations on 
what they are offering. I think clarity as to what this 
test will tell you, what it will not tell you. I think that 
needs to be clarified. And I think the colleagues need 
to understand before they offer it to their patients." 
(Participant 12, genetic clinician)
Third, participants voiced concerns about whether 
adequate resources—including laboratory and clini-
cian time and expertise—will be available to analyse 
and interpret sequence data and subsequent variant 
validation, with several feeling genetic departments will 
be ‘swamped’. Participants also raised concerns about 
phenotyping taking up the time of non- genetic clinicians, 
for example:
"presumably we would still have to do the phenotype 
data and certainly for clinicians, that’s the limiting 
step, filling out another form!"(Participant 23, non- 
genetic clinician)
Concerns were also expressed about the potentially 
very long turn- around times to results. Several partic-
ipants were also concerned that reports generated by 
labs were not ‘filtered’ enough, meaning a lot of work 
was still left for clinicians to do. Fourth, a few participants 
expressed concerns about disclosing results to patients 
both in terms of the amount of consultation time needed 
to discuss results with patients and families, and whether 
non- genetic clinicians have sufficient understanding to 
be able to interpret and return more complex results. See 
table 2 for additional illustrative quotes.
Attitudes towards offering secondary findings from genome 
sequencing
Perceived benefits
Participants perceived three main benefits of offering 
secondary findings from genome sequencing in clin-
ical practice. First, several participants felt that offering 
clinically actionable secondary findings in the clinical 
setting will provide the opportunity to identify patients 
at increased disease risk, allowing for improved disease 
prediction, prevention or early diagnosis. Second, several 
participants felt that including secondary findings will 
lead to research learning opportunities: for example, 
how we will learn more about the medical, social and 
financial impact of secondary findings on patients. Third, 
several participants felt that patients want or would want 
to receive secondary findings, suggesting that offering 
this type of information might be responsive to patients’ 
desires and preferences. See table 3 for illustrative quotes.
Concerns
The issue of whether secondary findings should be offered 
to patients divided participants, with some advocating a 
cautious adoption while collecting data on penetrance 
and outcomes, and others stating that secondary findings 
should not be offered at all. First, some were concerned 
that evidence is lacking regarding the penetrance of 
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Table 2 Health professionals’ attitudes (perceived benefits and concerns) towards moving genome sequencing into clinical 
practice
Content topic Illustrative quote
Perceived benefits
1. Improved diagnoses for patients “obviously we will get lots more diagnoses and that’s good, I think that’s good for everyone… 
and I think it helps, it helps for counselling, prevention, this type of things” (Participant 16, non- 
genetic clinician)
2. Contributions to knowledge base “It’s a technology that gives us access to, you know, vast quantities of information and if 
we as clinicians and scientists are able to interpret that in a meaningful way… and the more 
information we gather, then the easier it should be to interpret because we’ve got so many 
comparisons and so much more data to base our decisions on.” (Participant 18, non- genetic 
clinician)
3. Improved treatments for future 
patients
“…so if we can really correlate the clinical information with the genetic information and find 
these markers that will allow this personalised treatment, then we have a big step forward….” 
(Participant 11, non- genetic clinician)
Concerns   
1. Lack of evidence “I think it’s too early to know whether or not (whole genome sequencing) should become a 
routine part of clinical practice. I think we’ve now got sufficient evidence that whole exome 
sequencing can be very useful clinically… my own view is that we shouldn’t roll out whole 
genome sequencing clinically until we have objective scientific evidence that it’s superior to 
whole exome sequencing.” (Participant 14, genetic clinician)
2. Informed consent “What concerns me is that every single member of the 100 000 genomes team has said to 
me that it’s an hour to do the full consent process… I think most clinicians don’t have an hour 
spare to be going through that with patients… I think it’s very difficult for clinicians to do that 
genetic counselling. I don’t think it will be done particularly well, because it certainly won’t, it 
will be a 5 min process.” (Participant 17, non- genetic clinician)
3. Resources for analysis and 
interpretation
“It takes a lot of lab time to look at the data, it takes a lot of clinician time, to prepare the cases 
for a multidisciplinary team meeting…” (Participant 13, genetic clinician)
4. Interpretation and disclosure of 
results
“I think the problem is that other doctors think they’re trained but I don’t think they are… I’m 
much less confident about explanations of results… one sees all the time problems that arise 
because of that so results are over interpreted… so I am a bit worried about that kind of thing. 
Because I already see it…” (Participant 13, genetic clinician)
variants identified ‘completely incidentally’ and that we 
may be ‘over- estimating penetrance’ as a consequence.
Related to this, the second sub- theme that emerged was 
a concern that evidence is lacking regarding whether it is 
‘clinically useful’ to return secondary findings to patients, 
particularly if they do not have a known family history of 
the associated condition. One participant said that this 
‘opens a can of worms’.
The third subtheme that emerged was concern about 
the potential psychological impact of the results on partic-
ipants, such as causing ‘anxiety’. One participant asked, 
“How do you stop people from suffering unduly from 
getting these results back?” (Participant 8, consenter), 
while another asked, “are you opening up Pandora’s 
box?” (Participant 5, consenter). One participant likened 
secondary findings to picking up aneurysms incidentally 
on brain scans (see table 3).
The fourth sub- theme that emerged was a specific 
concern that non- genetic clinicians are not prepared 
to discuss secondary findings. One participant was 
concerned that doctors without ‘a genetics training 
background’ might misinterpret secondary findings and 
that this could lead to ‘false reassurance’ (Participant 6, 
consenter). Another emphasised that non- genetic clini-
cians couldn’t decide whether mutations were ‘real’ or 
what the associated disease ‘risk’ would be (see table 3). 
Related to this concern, some participants felt that, if 
secondary findings were to be offered, return of results 
should only be done by genetic experts and/or via 
Genetics Departments. One participant stated that he 
felt it would be ‘completely unsafe’ for non- genetic clini-
cians to offer such findings to patients. Some also felt that 
Genetics Departments already have referral pathways in 
place (eg, cancer screening) and that this was another 
reason that secondary findings should only be offered by 
genetic clinicians, if at all.
Fifth, some participants were concerned about what 
their clinical recommendations for their patients would 
be, and how they would advise their patients, based on 
secondary findings. Linked to this, some participants were 
concerned about whether the ‘list’ of secondary findings 
would change and whether patients would be ‘re- tested’ 
if/when that did happen.
The final sub- theme that emerged, reflecting all of the 
concerns above, was that it would be more straightforward 
if secondary findings were not offered in clinical practice. 
Several participants stated that clinicians already offer 
clinical exome sequencing and that secondary findings 
are not offered as part of that clinical service in the UK. 
These participants felt that the same approach should be 
taken with clinical genome sequencing. See table 3 for 
illustrative quotes.
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Table 3 Health professionals’ attitudes (perceived benefits and concerns) towards secondary findings
Content topic Illustrative quote
Perceived benefits
1. Improved prediction, prevention or early 
diagnosis of complex diseases for current 
patients
“…and also I think it’s part of offering, it’s part of helping people to get healthier. If we can 
prevent things happening or help them earlier in the stage of something happening, I think 
it’s part of our duty to actually do that.” (Participant 7, consenter)
2. Opportunity to advance research “And as I said as we learn more we’re going to appreciate number one how people 
receive that information and the impact it has on them, sort of medically as well as 
socially, financially et cetera…. So yeah I think it’s just going to be a moving field 
and we’re going to learn from mistakes, but you know probably gain some of the 
understanding.” (Participant 18, non- genetic clinician)
3. Being responsive to what patients want “Yeah I think you know, if there’s something you can do about it, then I think that’s fine 
yes. I think a lot of people would want to know and they can be consented up front.” 
(Participant 22, genetic clinician)
Concerns   
1. Evidence is lacking regarding the 
penetrance of variants identified 
incidentally
“…the principle I think is sound but I think what we may find is that the penetrance of a 
lot of these things is not as high as we thought it was and that maybe if, if you ascertain 
somebody as a carrier of a pathogenic mutation completely incidentally what does that 
mean in terms of penetrance, I think we may be over, over estimating penetrance…” 
(Participant 13, genetic clinician)
2. Evidence is lacking regarding whether 
it is clinically useful to return secondary 
findings
“I think they (secondary findings) should be done when it’s clinically necessary not just for 
the hell of it” (Participant 4, consenter)
3. Potential psychological impact of the 
results
“…even when you do find your aneurism and… you tell them that their risk of developing 
something is very low but they tend to walk around thinking they’ve got a time bomb in 
their head anyway and the same [is] going to apply with genetics. Incidental findings as 
well probably much more so in fact.” (Participant 19, non- genetic clinician)
4. Non- genetic clinicians are not prepared 
to discuss secondary findings with patients
“…if we were to offer this for routine clinical practice, you know, in a neurological 
hospital how can we possibly decide whether, you know, a mutation in a cancer gene is 
a polymorphism or real or what’s the risk you know? We cannot counsel patients on all 
these other things.” (Participant 21, non- genetic clinician)
5. Not clear what clinical recommendations 
for patients would be based on some 
secondary findings
“I think in BRCA and the MMR gene there’s plenty of evidence out there. So you know 
you’d have to have [screening], so it needs to be recurrent mutations that are definitely 
associated and so what do you do then if you go and find something else. I don’t know 
whether these people should be on screening or not ” (Participant 9, genetic clinician)
6. More straightforward if secondary 
findings were not offered as part of 
genome sequencing in clinical practice
“Yeah well again I would not treat this as any way different than to the clinical exome we 
do here or the exome we do on research. You look at the things that you are interested 
in.” (Participant 11, non- genetic clinician)
Views on how genome sequencing should be delivered in 
clinical practice
Participants’ views on genome sequencing in clinical 
practice fell into three overarching themes.
Non-genetic clinicians can offer genome sequencing in clinical 
practice as long as they have appropriate training and are 
supported by healthcare professionals with genetics expertise
Participants felt that non- genetic clinicians should be 
able to offer genome sequencing to patients in their 
clinical practice but that adequate training and support 
from genetics teams were critical (table 4). One partici-
pant stated that ideally consent would be conducted by 
a genetic counsellor but that this is not practical. For 
many participants, appropriate training was key although 
most felt that the consent process did not need to be 
conducted by a genetic expert, they also felt that anyone 
offering genome sequencing consent to patients should 
only do so after adequate training.
One participant emphasised that non- genetic clini-
cians can take responsibility for the consent process for 
genome sequencing ‘but there needs to be the appro-
priate support systems in place’, and another suggested 
that clinicians could consent patients but that patients 
might at least need the ‘option’ of being able to talk to 
and ask questions of a genetic counsellor, genetic nurse 
or other genetic specialist at the time of consent.
Many participants felt that non- genetic clinicians 
should be involved in the return of results to patients, but 
highlighted that they would need support from genetics 
departments/teams in interpreting and discussing 
complex findings, including secondary findings and 
more complex main findings. Notably, in this context, 
several clinicians spoke of existing working relationships 
between genetics and other specialty groups and the 
importance of working in MDTs, for example:
"they know we’ll be around when the results come 
back if they’re not clear cut and they need somebody 
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Table 4 Health professionals’ views on whether/how genome sequencing should be delivered by non- genetic clinicians in 
clinical practice
Content topic Illustrative quote
Non- genetic clinicians can offer genome sequencing in clinical practice as long as they have appropriate training and are supported by 
healthcare professionals with genetics expertise
1. Not practical to have genetics experts 
(eg, genetic counsellors) to offer & return all 
results
“I mean in an ideal world actually what you’d do, what you would have is someone 
additional in your clinic perhaps a Genetic Counsellor who was working in the clinic 
who could do that kind of thing, but that’s not how it works, it’s not how we deploy our 
resources… I think it will be offered through other health professionals…” (Participant 
13, genetic clinician)
2. Non- genetic clinicians can offer genome 
sequencing as long as they have adequate 
training
“With appropriate training I think it probably could be offered by, by appropriate 
professionals…if it was a hospital Consultant and they had the time to really discuss 
it and they had the appropriate knowledge and training and the confidence to give the 
results back then I don’t see that being a problem…” (Participant 6, consenter)
3. Non- genetic clinicians can offer genome 
sequencing as long as they have sufficient 
support from genetic departments / teams 
in interpreting, returning and/or discussing 
complex findings
“I think (offering genome sequencing) does need to be linked closely with genetics… 
I think that’s key because otherwise you could potentially think something is relevant 
and pathogenic when actually it might not be or it’s complicated with another variant… 
we must never underestimate the complexity of it… So I suppose that means that you 
would and should need access to your genetics team.” (Participant 23, non- genetic 
clinician)
“So if you don’t know anything about the genes then obviously the discussion of the 
findings should be left to somebody who has experience of genetics I do think yes.” 
(Participant 11, non- genetic clinician)
to discuss it with because they do that all the time 
with other tests that they request… They know we’re 
here to help with the interpretation of that, they just 
need to know enough to be able to offer the right 
genetic test to the right patient, at the right time." 
(Participant 14, genetic clinician)
Views on training content
Participants made a number of recommendations about 
what training non- genetic clinicians will need in order 
to ensure they have adequate knowledge to receive 
informed consent for genome sequencing from patients. 
In addition to having a knowledge of basic genetics, they 
would need to emphasise that genome sequencing is 
optional, manage patients’ expectations regarding turn-
around time for results, and admit if they do not know 
the answer to a patient’s questions. Participants also felt 
that non- genetic clinicians need guidance regarding who 
should be offered genome sequencing. The recommen-
dations for training content are summarised in table 5.
Views on training delivery
In addition to the content of the training, participants 
expressed views about how training for non- genetic clini-
cians might best be delivered, with several suggesting that 
all doctors and nurses should be trained at medical or 
nursing school as part of the curriculum. Participants 
also suggested that online training was helpful for some 
types of learning (eg, basic genetics) and that this should 
be interactive (eg, with videos) rather than only static 
written information, but that other types of learning (eg, 
counselling) needed to be in- person (eg, shadowing). 
Several people felt that non- genetic clinicians would be 
most likely to attend half- day or 1- day training days or 
study days, rather than longer modules. Several partic-
ipants also felt that such training should be mandatory 
(including regular and refresher training) and that there 
should be some kind of ‘National Standard’, ‘certificate’ 
or ‘certification’. Finally, several participants talked about 
the key role that genetic experts are already playing and 
will continue to play in training and ‘upskilling’ their 
non- genetic colleagues, by working closely with them 
and supporting them, and via ‘buddying systems’ and 
‘genomics champions’. See table 6 for further details and 
additional illustrative quotes.
DISCuSSIOn
In this study, we found that healthcare professionals with 
experience of delivering genome sequencing in the UK 
NHS as part of the 100 000 Genomes Project had mixed 
views regarding moving genome sequencing into clin-
ical practice. Positive views were expressed regarding the 
potential for genome sequencing to improve diagnoses 
of rare diseases, contribute to the rare disease knowl-
edge base and lead to improved treatments in the future. 
However, some concerns were also expressed. Some partic-
ipants’ worries were primarily about whether healthcare 
professionals in genetics and non- genetics departments 
have adequate resources to explore the tiered variant 
report that is returned, undertake variant interpretation, 
conduct additional phenotyping and technically validate 
results to issue a report. They also had reservations as to 
whether non- genetic clinicians are adequately prepared 
to disclose results to patients. Similar concerns about 
whether clinicians, particularly non- genetic clinicians, 
have the necessary resources and training to include 
genome sequencing in their practice have been reported 
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Table 5 Health professionals’ views/recommendations for content of training for non- genetic clinicians
Content topic Illustrative quote
Basic genetics “All doctors need to be trained in the basics of genetics” (Participant 11, non- genetic clinician)
Guidance regarding who should be 
offered whole genome sequencing
“I think we should, we need to have guidelines as to who should be the right candidate and as 
long as we have, we know that, then I think any professional would be able with the requisite 
training and who’s informed about the indications, but(…) then yes they should be able to offer 
it.” (Participant 15, non- genetic clinician)
Limitations/process/managing 
patients expectations
“So I think it’s essential that you understand the process, you understand the limitations… you 
have to give them honest expectations of process. And I think that’s your own responsibility 
to try and understand the science of it. So yeah I think that’s the most important thing not to 
give people false hope, not selling this as some magic new technology to give the answer to a 
problem. And the difficulty of interpretation and just why it takes so much time.” (Participant 18, 
non- genetic clinician)
Build confidence in ability to 
answer patients’ questions
“if you are not confident you cannot discuss genetic, because parents will ask questions. If you 
don’t know the answer, then not going to work. You have to be confident when you have these 
discussions with parents I think.” (Participant 13, genetic clinician)
Admit if don’t know answers to 
patients’ questions
“The offering it to them, if you’re not sure of the answer tell them that you will find out, don’t 
make it up.” (Participant 21, non- genetic clinician)
Emphasise patient has the option 
to decline
“I think what’s happening also sometimes, when a consultant offers something to the patient, 
whatever it is, the patients are very keen to say yes because it’s their specialist telling them 
something and rightly they think it’s an important thing, but they don’t always know that they 
have the right or the option to actually refuse it. So just to stress to the consultant that they have 
to make that option very clear. This is a great test which I agree with but “You don’t have to take 
part” usually is left out because we don’t have time to do that. And I would love a little bit less of 
“Great” and a little bit more of “You have the option of not taking part”.” (Participant 7, consenter)
Allow adequate time to inform 
patients properly and to make their 
decision
“what we offer them has to be explained properly so they can make an informed consent and 
not using that to our advantage, just to get someone to consent into a study… What we’re 
offering, we think it’s this and that, and that, make it very clear, and let them make the informed 
consent and to take the decision in their time. Some people might need a little bit more time than 
others…” (Participant 7, consenter)
How to understand/deal with a 
genetics report
“How do you annotate a variant? What does it mean if it’s a class one, two, three, four, five, and 
how do you interpret that?(…)So I think these are things that just need to be clear to everybody 
how to understand a genetic report, what does make a class three, class four, whatever, but I 
think that’s any clinician though.” (Participant 11, non- genetic clinician)
in a US study exploring health professional experiences 
of returning genome sequencing results.8 Participants in 
the present study were also concerned about secondary 
findings from genome sequencing being offered in clin-
ical practice. Although perceived benefits of offering 
secondary findings that included improved prediction 
and prevention of complex diseases, advancing research 
and being responsive to what patients want were discussed, 
a number of concerns were also voiced. Concerns about 
reporting secondary findings to patients included lack of 
evidence regarding the possibly lower penetrance of vari-
ants identified incidentally, lack of evidence regarding 
whether it is clinically useful to return such results, how 
clinicians should advise patients to act based on the 
results, the potential for such findings to cause patients 
anxiety and again that non- genetic clinicians do not 
have the necessary expertise to counsel patients about 
secondary findings. Overall, however, participants felt 
that non- genetic clinicians will be able to offer genome 
sequencing to patients in clinical practice, as long as they 
have adequate training and support from colleagues with 
expertise in genetics, particularly for more challenging 
cases and complex findings. They also offered specific 
recommendations for what that training and support 
should look like and how it should be delivered.
Our findings have implications for clinicians and policy- 
makers concerned with moving genome sequencing into 
clinical practice. Our findings suggest that non- genetic 
clinicians will be able to support patients in their decision- 
making, receive consent and order genomic sequencing 
tests as long as they have adequate training and support 
from genetic teams to help with interpretation of results 
and explanations to patients in complex cases. Clear proto-
cols and processes for referral to genetics for patients to 
discuss complex main findings or if a secondary finding 
is identified are also needed. In addition to being offered 
as part of medical school and nursing training, educa-
tion for non- genetic health professionals about genome 
sequencing technology (eg, basic genetics, processes, 
limitations and interpreting genetics reports) may be 
delivered online as long as it includes interactive multi-
media components. Education about supporting consent 
and communicating results to patients may be better 
delivered through in- person training, and shadowing in 
the clinic may also be valuable. An important element of 
training in the future is that genetic experts need to play 
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Table 6 Health professionals’ views/recommendations for training for non- genetic clinicians
Training type Illustrative quote
Medical school “Yeah. I think in the medical school.” (Participant 11, non- genetic clinician)
Nursing curriculum “Well I think it will be part of the curriculum in the future. It will just have to become part of nursing curriculum.” 
(Participant 8, consenter)
Online training “…the actual genetic concepts don’t necessarily need to be in person they could be done with online modules” 
(Participant 6, consenter)
Shadowing “you shadow a consultant or a genetic counsellor or someone before you get signed off to go and consent 
on your own…So when you do the online training, it gives you the knowledge but then when you're doing it 
practically, it gives you the ability to be able to speak to the patients, answer their questions as the PC doesn’t 
speak to you, doesn’t throw in little scenarios whereas in real life we know it doesn’t go that straightforward, so 
doing it with someone and having somebody there actually works” (Participant 10, consenter)
Role playing “talking to a patient, the counselling aspect of it, the understanding of the way that people deal with bad news 
and understand risk I think is better done in person. …the patient interacting side of it has to be done through 
face to face training…” (Participant 6, consenter)
Day or half- day 
training
“Yeah, I mean there are all sorts of courses available. The vast majority of clinicians haven’t got time to do it 
and so they’re more likely to come to a half day or a 1 day training course than they are to sit down and do 
some on line training. [some clinicians] haven’t got the time to take a year or two out to do a Masters, they want 
something much more quick and practical and off the shelf and ready now, that just gets them up to speed so 
that they know enough knowledge to know which test to offer to whom and when.” (Participant 14, genetic 
clinician)
“I guess an open training session would be useful, in terms of something like an FAQ sort of session as to what 
are the expected questions from families and you know how to [answer] them, that sort of a training would be 
helpful.” (Participant 15, non- genetic clinician)
Training should be 
mandatory/national 
Standard/certification
“Mandatory is a way of keeping on top of who’s actually been trained, when they were trained and you get your 
refresher so, yeah, you do your basic, you get your certificate.” (Participant 10, consenter)
Genetic clinicians 
train non- genetic 
colleagues/buddying 
systems and 
genomics champions
“So what we’re trying to set up is a kind of a buddying system where we will try and have clinical genetics 
working with sort of genomics champion in that speciality…. So that the genomics champion from the 
speciality who will put themselves forward as a sacrificial lamb, and the genetics consultant or genetics 
counsellor with experience, will kind of discuss and agree what the steps are with feeding that information 
back to patients. … So what’s happened is our genetics teams have gone to the cancer MDTs, disease specific 
cancer MDTs and they’re trying to help people understand about the difference between somatic mutations 
and germ line mutations. And whether they are clinically actionable… And I think that is working quite well and 
it’s quite labour intensive for the genetics team, but they are you know, working with particular oncologists who 
want to learn all about this. It’s that kind of partnership between genetics and then somebody who’s prepared 
to be the genomics champion from the speciality.” (Participant 9, genetic clinician)
FAQ, frequently asked questions; MDT, multidisciplinary team.
a key role in training and then supporting non- genetic 
clinicians in understanding sequence data and interpre-
tation of results returned to them from the laboratories 
and results disclosure to patients.
Our finding that most participants felt health profes-
sionals from non- genetic backgrounds should be able 
to offer genome sequencing with support from genetics 
colleagues, perhaps reflects the increasing recognition 
that genetics/genomics is relevant to all areas of medicine 
and should therefore be ‘mainstreamed’.13–15 As others 
have concluded, it is inevitable that genomic sequencing 
will be used more frequently in mainstream clinical prac-
tice,16 and that input from genetic professionals will be 
needed for more complex cases, in education and for 
the cross- discipline collaboration that will be essential 
for classifying variants and understanding phenotypes.8 16 
As the UK Genomic Medicine Service is established, it 
is important that research continues into how genome 
sequencing can best be offered, and how genetic and 
non- genetic professionals can work together to ensure 
patients with rare diseases have access to a Genomic 
Medicine Service that is effective and equitable.
Approaches to the return of secondary findings from 
genomic sequencing in both research and clinical settings 
have varied widely, with some programmes choosing to 
report from a long list of secondary findings and others 
opting not to offer any secondary findings at all. Profes-
sional guidelines for practice also differ. The American 
College of Medical Genetics (ACMG) recommends that 
all laboratories conducting clinical genome or exome 
sequencing for patients should search for DNA variants 
that are classified as pathogenic in a minimum list of 59 
medically actionably genes, and that these secondary find-
ings should be reported to patients, regardless of the orig-
inal reason for the sequencing being done.17 Canadian18 
and European guidelines19 have taken a more conserva-
tive approach, and do not recommend secondary findings 
are looked for in the clinical context at the present time. 
In the 100 000 Genomes Project, participants could opt 
to have the project scientists look for secondary findings 
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in genes on a more limited list than the ACMG guidelines 
list (at the time of our interviews no secondary findings 
had been reported to clinicians or patients). The views 
of our participants regarding secondary findings suggest 
two possible ways forward. The first option is simply not 
to offer secondary findings in clinical practice, at least not 
until further evidence regarding outcomes is obtained. 
As some of our participants stated, this would be consis-
tent with how many clinical exomes are already managed 
today. However, as other participants stated, there are 
potential advantages to offering secondary findings, for 
example, this could provide much needed evidence on 
both the outcomes of variants identified incidentally, 
provided care is taken to ensure the long- term follow- up 
required to collect such research data. Thus, the second 
option is to provide the training and resources to be 
able to offer secondary findings in clinical practice and 
to encourage patients to consent to research alongside 
their clinical care. In the words of Les Biesecker,20 “[a]s 
a field, we should take full advantage of all opportunities 
to study these variants by searching them out, returning 
them to patients and research participants, and studying 
their utility for predictive medicine.”
Strengths of our study include that participants came 
from several hospitals and had a range of clinical back-
grounds, and that all participants’ perspectives were 
informed by actual personal experience of offering 
genome sequencing to patients within a healthcare 
service, although as part of a research study. These health-
care professionals were among the first to offer genome 
sequencing within the UK NHS, and so they have insights 
that go beyond attitudes expressed in previous studies 
which mostly occurred before genome sequencing 
was available and so participants did not have this real- 
world experience.21 In some earlier studies, participants’ 
views were often extremely positive, including regarding 
secondary findings.22 23 For example, in a 2013 US survey, 
96% of clinical genetic healthcare professionals stated 
they believed secondary findings should be offered to 
adult patients.22 The views expressed by our participants 
are more aligned with the more cautious views expressed 
by the genetic professionals, who also had experience of 
delivering genome sequencing where secondary find-
ings were offered, in a recent UK qualitative interview 
study focused on secondary findings.11 These differences 
may, however, also reflect overarching differences in the 
approach to reporting secondary findings between health 
professionals in the UK and the USA, where many of the 
studies to date have been conducted, as the ACMG has 
advocated the reporting of a wide range of secondary 
findings from clinical genome sequencing since 2013.
Weaknesses of our study include the small number of 
participants, meaning the findings may be potentially 
less generalisable to the wider population of health-
care professionals, and comparisons could not be made 
between genetic and non- genetic clinicians. In addition, 
the healthcare professionals were recruited from only 
two of the 13 GMCs in the UK, and so the findings may 
not generalise to other geographic locations. The study 
was also conducted before most of the healthcare profes-
sionals had disclosed results to patients, so questions 
regarding potential benefits are more hypothetical.
In conclusion, genetic and non- genetic healthcare 
professionals responsible for delivering clinical genome 
sequencing in the UK have largely positive views of 
genome sequencing in terms of improving diagnostic 
yield, but also have concerns and recommendations 
about practical aspects of delivery. Additional empirical 
research evidence will be useful to inform policy and 
practice, including how genome sequencing compares 
to exome sequencing and the clinical utility of secondary 
findings.
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